NCT04338867View on ClinicalTrials.gov

Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

March 1, 2020

Study Completion Date

March 1, 2020

Conditions
Phase II Clinical TrialNinety-six Histologically Confirmed NSCLC Patients With BMRandomized 1:1 to Received TN Plus WBR or Only WBRICPFS Evaluated by Two Blinded and Independent Radio-oncologist With MRI
Interventions
RADIATION

Whole-brain radiotherapy

Patients were randomized 1:1 and allocated to either the control arm who received whole-brain radiotherapy (WBRT) or the experimental arm who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN)

Trial Locations (1)

14080

National Cancer Institute of Mexico, Mexico City

All Listed Sponsors
lead

Instituto Nacional de Cancerologia de Mexico

OTHER

NCT04338867 - Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients | Biotech Hunter | Biotech Hunter